Response rates to second-line STS therapies, including pazopanib, are typically <10% with median PFS <5 months, underscoring demand for predictive biomarkers. Transcriptomic profiling of 11 paired pre ...

Higher-performing Medicare accountable care organizations are smaller and characterized by real-time information sharing, ...

Phase 3 TRIUMPH readouts show dose-dependent mean weight loss up to ~30% at 104 weeks in obesity and ~21% in T2D, with ...

Following the Steward Health Care bankruptcy, Massachusetts law HB 5159 mandates rigorous oversight of for-profit health care ...

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA. The FDA has granted an accelerated approval to the regimen ...

A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, ...

Obesity, MASH, and the Metabolic Dysfunction That Connects Them,' Jaime Almandoz, MD explores the following questions: As an endocrin ...

Forecasted cost growth was highest in fully insured arrangements, consistent with constrained data rights; only about 60% felt able to audit full claims files. Employers with complete claims data ...

The disparity in outcomes between pediatric and young adult patients with ALL is multifactorial, explained Emily K. Curran, MD.

Effective October 13, 2026, federal financial participation is barred for specified pharmacologic and surgical interventions for Medicaid beneficiaries under 18 and CHIP enrollees under 19. CMS ...

Setmelanotide produced a mean body mass index (BMI) reduction of 16.5% in patients with acquired hypothalamic obesity, compared with a 3.3% increase among those receiving placebo, according to trial ...